Devonian Health Group Inc

Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec and currently employs 6 full-time employees. The company went IPO on 2014-09-09. The firm is focused on developing prescription botanical drugs from plant materials and algae for the treatment of inflammatory autoimmune diseases, including but not limited to ulcerative colitis and atopic dermatitis. The company is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health conditions related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., is focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.